Clearside Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>CB</div>
CLSD -- USA Stock  

USD 3.79  0.13  3.55%

The upcoming quarterly report is expected on the 10th of March 2021. The stock experiences an active upward rally. Clearside Biomedical Average Assets are projected to decrease significantly based on the last few years of reporting. The past year's Average Assets were at 27.01 Million. The current year Average Equity is expected to grow to about 11.5 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (29.7 M). As many passive investors are finally getting excited about healthcare space, Clearside Biomedical could be a good starting point. We will evaluate why recent Clearside Biomedical price moves suggest a bounce in February.
Published over two weeks ago
View all stories for Clearside Biomedical | View All Stories
What is February outlook for Clearside (NASDAQ:CLSD)?
This firm currently holds 2.05 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest Clearside Biomedical is not taking enough advantage from borrowing. The company has a current ratio of 1.91, which is within standard range for the sector. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Clearside Biomedical has an asset utilization ratio of 46.64 percent. This indicates that the company is making $0.47 for each dollar of assets. An increasing asset utilization means that Clearside Biomedical is more efficient with each dollar of assets it utilizes for everyday operations.
Clearside Biomedical financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Clearside Biomedical, including all of Clearside Biomedical's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Clearside Biomedical assets, the company is considered highly leveraged. Understanding the composition and structure of overall Clearside Biomedical debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Clearside Total Liabilities

Clearside Biomedical liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Clearside Biomedical has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Clearside Biomedical balance sheet include debt obligations and money owed to different Clearside Biomedical vendors, workers, and loan providers. Below is the chart of Clearside short long-term liabilities accounts currently reported on its balance sheet.
You can use Clearside Biomedical financial leverage analysis tool to get a better grip on understanding its financial position

How important is Clearside Biomedical's Liquidity

Clearside Biomedical financial leverage refers to using borrowed capital as a funding source to finance Clearside Biomedical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Clearside Biomedical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Clearside Biomedical's total debt and its cash.

A Deeper Perspective

Clearside Biomedical reported the previous year's revenue of 9.82 M. Net Loss for the year was (14.19 M) with profit before overhead, payroll, taxes, and interest of 2.17 M.

Liabilities Breakdown

11.9 M
Current Liabilities
6.7 M
Long-Term Liabilities
Total Liabilities18.57 Million
Current Liabilities11.87 Million
Long-Term Liabilities6.7 Million

Over 3 percent surge for Clearside Biomedical. What does it mean for shareholders?

Information ratio is down to 0.29. It may indicate a possible volatility dip. Clearside Biomedical shows above-average downside volatility for the selected time horizon. We advise investors to inspect Clearside Biomedical further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Clearside Biomedical future alpha.

Our Conclusion on Clearside Biomedical

When is the right time to buy or sell Clearside Biomedical? Buying stocks such as Clearside Biomedical isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis. With an optimistic outlook on your 30 days horizon, it may be a good time to purchase new shares of Clearside or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Clearside Biomedical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Clearside Biomedical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com